| Note de synthèse: position de l’OMS sur les vaccins contre la variole et la mpox (orthopoxvirus) | World Health Organization (WHO) | 2024 | Guidance | Français, Anglais |
| Vaccin LC16m8 (vaccin lyophilisé vivant atténué) contre la variole et la variole du singe : directives provisoires | World Health Organization (WHO) | 2025 | Guidance | Français, Anglais |
| Vaccin contre la variole et la mpox MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) : directives provisoires | World Health Organization (WHO) | 2024 | Guidance | Français, Anglais |
| ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of age | European Medicines Agency | 2024 | Guidance | Anglais |
| Off-label vaccine use: explanatory note for countries | World Health Organization (WHO) | 2024 | Guidance | Anglais |
| Regulatory & Policy Considerations for Mpox Vaccines in African Countries | World Health Organization (WHO), European Medicines Agency, Bavarian Nordic | 2025 | Presentation | Anglais |
| Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label use | World Health Organization (WHO) | 2025 | Presentation | Anglais |
